Stocks and Investing Stocks and Investing
Tue, January 31, 2023

Brian Abrahams Maintained (XENE) at Buy with Increased Target to $51 on, Jan 31st, 2023


Published on 2024-10-28 01:12:56 - WOPRAI, Brian Abrahams
  Print publication without navigation


Brian Abrahams of RBC Capital, Maintained "Xenon Pharmaceuticals Inc." (XENE) at Buy with Increased Target from $49 to $51 on, Jan 31st, 2023.

Brian has made no other calls on XENE in the last 4 months.



There are 5 other peers that have a rating on XENE. Out of the 5 peers that are also analyzing XENE, 0 agree with Brian's Rating of Hold.



These are the ratings of the 5 analyists that currently disagree with Brian


  • Paul Choi of "Goldman Sachs" Initiated at Strong Buy and Held Target at $60 on, Wednesday, December 14th, 2022
  • Joseph Thome of "Cowen & Co." Initiated at Buy on, Monday, December 12th, 2022
  • Mohit Bansal of "Wells Fargo" Initiated at Buy and Held Target at $50 on, Monday, November 28th, 2022
  • Yatin Suneja of "Guggenheim" Maintained at Strong Buy with Decreased Target to $49 on, Friday, November 11th, 2022
  • Danielle Brill of "Raymond James" Initiated at Buy and Held Target at $52 on, Wednesday, October 19th, 2022
Contributing Sources